IRVINE, Calif., May 29, 2018 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC), a commercial stage medical device company focused on Magnetic Resonance Imaging (MRI)-Guided Neurosurgical procedures, today announced that its ClearPoint® Neuro Navigation System will be featured in a symposium, entitled “ClearPoint Precision Guided Therapy – Making the Most of Your Magnet,” on Sunday, June 3, 2018 at the Biennial Meeting of the American Society for Stereotactic and Functional Neurosurgery (ASSFN) taking place in Denver, Colorado June 2-5, 2018.
The symposium will feature a variety of case studies including DBS lead placement, laser ablation and convection enhanced drug delivery utilizing the sub-millimetric precision of real-time MRI navigation with ClearPoint. Dr. Mark Richardson, Director of Epilepsy and Movement Disorders Surgery at University of Pittsburgh Medical Center will discuss his experience with targeting methods, including the real-time visualization of the delivery of novel new drugs to the putamen for Parkinson’s Disease. Dr. G. Rees Cosgrove, Director of Epilepsy and Functional Neurosurgery at Brigham and Women’s Hospital in Boston, will discuss workflow techniques for efficient utilization of the MRI, including anatomic targeting of the VIM for the treatment of essential tremor, and how these best practices have enabled him to routinely perform two procedures in the same magnet each day.
“We are excited to participate in this symposium with two clear and very relevant goals for today’s neurosurgery environment,” commented Joe Burnett, President and CEO of MRI Interventions. “First, we will showcase how our ClearPoint technology enables surgeons to decide, guide and confirm each and every step of the neurosurgical procedure, creating a complete step-by-step documentation of how the procedure was done with safety and accuracy as the number one priority. Second, we will show that achieving this level of precision across many different case types does not have to come at the expense of time, and that multiple procedures can be routinely performed in the same day, in the same MRI scanner. This is not theoretical, but rather the audience will hear directly from two top neurosurgeons taking advantage of this technology today. We believe this will be a very practical workshop which will provide actionable information the attendees can immediately apply to their own practice.”
The ASSFN covers the latest clinical and research advances in epilepsy, movement disorders, pain, neural engineering, and emerging technologies in functional neurosurgery. ASSFN attendees are invited to visit MRI Interventions’ booth (#204) to learn about the ClearPoint System platform.
About MRI Interventions, Inc. and the ClearPoint Neuro Navigation System
Building on the imaging power of magnetic resonance imaging (“MRI”), MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain.
The ClearPoint Neuro Navigation System allows surgeons to plan, target, and adjust trajectories of electrodes, catheters and needles under real time MRI-guided visualization without attaching a large, metal stereotactic headframe to the patient. Real time MRI imaging provides the surgeon with current views of the patient’s brain anatomy at the time of surgical planning, device alignment, and navigation of the device to target, which is designed to improve accuracy and reduce risk of brain shift associated with standard imaging techniques. In addition, the entire ClearPoint procedure takes place in an MRI suite and eliminates the need to move the patient to and from an operating room and an MRI scanner. The ClearPoint Neuro Navigation System, which has received 510(k) clearance and is CE marked, utilizes a hospital’s existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain.
For more information, please visit www.mriinterventions.com.
Forward-Looking Statements
Statements herein concerning MRI Interventions, Inc.’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the Company’s ability to obtain additional financing; estimates regarding the sufficiency of the Company’s cash resources; future revenues from sales of the company’s ClearPoint Neuro Navigation System products; and the company’s ability to market, commercialize and achieve broader market acceptance for the company’s ClearPoint Neuro Navigation System products. More detailed information on these and additional factors that could affect the company’s actual results are described in the “Risk Factors” section of the company’s Annual Report on Form 10-K for the year ended December 31, 2017, and the Company’s Quarterly Report on Form 10-Q, both of which have been filed with the Securities and Exchange Commission.
Contact:
Wendelin Maners, VP, Marketing
MRI Interventions, Inc.
949-900-6833
Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com